Key facts
- MiniMed and Abbott have expanded their partnership.
- The agreement focuses on integrating dual glucose-ketone sensors.
- The new sensors aim to simplify diabetes management.
- MiniMed is a leader in diabetes technology.
MiniMed (NASDAQ: MMED), a global leader in diabetes technology, has announced an expanded agreement with Abbott to collaborate on integrating Abbott's dual glucose-ketone sensors into MiniMed's product offerings. This strategic move is designed to broaden the choice available to individuals managing diabetes and to simplify their daily routines. The partnership builds upon the existing collaboration between the two companies, further solidifying their commitment to advancing diabetes care through technological innovation.